1755-3768/asset/olbannercenter.gif?v=1&s=baf172706d8b0315485b0acf45bb6cfebe7a6ecc)
Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study
Article first published online: 18 SEP 2006
DOI: 10.1111/j.1600-0420.2006.00754.x
Additional Information
How to Cite
Ozturk, F., Ermis, S. S. and Inan, U. U. (2007), Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study. Acta Ophthalmologica Scandinavica, 85: 80–83. doi: 10.1111/j.1600-0420.2006.00754.x
Publication History
- Issue published online: 5 OCT 2006
- Article first published online: 18 SEP 2006
- Received on May 12th, 2005. Accepted on May 25th, 2006.
- Abstract
- Article
- References
- Cited By
Keywords:
- bimatoprost;
- timolol;
- dorzolamide;
- primary open-angle glaucoma;
- ocular hypertension
Abstract.
Purpose: To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol-dorzolamide combination in patients with primary open-angle glaucoma (POAG) or ocular hypertension during 6 months of treatment.
Methods: A sample of 65 patients with a diagnosis of POAG or ocular hypertension were randomized to receive either bimatoprost 0.03% once daily or timolol-dorzolamide combination twice daily. Study visits occurred at baseline and after 2 weeks and 1, 3 and 6 months of therapy. Intraocular pressure (IOP) measurements were performed at 12.00 hours at all study visits and also at 08.00 hours and 16.00 hours at baseline and 6-month visits. At each visit, local and systemic side-effects that occurred during the treatment period were recorded. Student's t-test was used to compare the differences between IOP values.
Results: Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05). In the bimatoprost-treated group, the IOP reduction was 6.2 ± 1.8 mmHg, whereas it was 6.5 ± 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment. The difference was not statistically significant (p = 0.48).
Conclusions: The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up. Both bimatoprost and the timolol-dorzolamide combination were well tolerated. Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.